<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174300</url>
  </required_header>
  <id_info>
    <org_study_id>UCV/2018-2019/076</org_study_id>
    <nct_id>NCT04174300</nct_id>
  </id_info>
  <brief_title>Molecular Response to Custom Manual Physiotherapy Treatment of Chronic Fatigue Syndrome (CFS) &amp; Fibromyalgia</brief_title>
  <official_title>Molecular Response to Custom Manual Physiotherapy Treatment of Chronic Fatigue Syndrome (CFS) &amp; Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Universidad Católica de Valencia San Vicente Mártir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Universidad Católica de Valencia San Vicente Mártir</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FM) are complex diseases often presenting
      overlapping symptomatology. Manual therapy (MT) protocols report benefits for pain treatment
      of FM, but the underlying mechanisms for patient improvement remain unknown.

      The main goal of this study is to assess the molecular changes associating to mechanical and
      additional MT triggers, possibly involved in patient symptom improvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Female patients fulfilling Canadian and International CFS criteria, presenting comorbid
      Fibromyalgia assessed by 2010 ACR (American College of Rheumatology), age 45-55 and BMI&lt;35
      (N=40) will be subjected to physiotherapy treatment consisting on 8 sessions of manual
      therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N by a single
      operator (Collegiated Physiotherapist). Blood samples (10-20mls/participant) will be obtained
      before and after first treatment, and after fourth and last treatment to determine molecular
      blood changes associated to the physiotherapy protocol applied. PBMC (Peripheral Blood
      Molecular Cells) transcriptome before and after treatments (RNAseq) will be studied towards
      identifying treatment-associated differential expression, mechanomiR profiles included.
      Patient health status with treatment will be monitored by FIQ, MFI and SF-36 questionnaires,
      in addition to an anonymized satisfaction questionnaire to register potential undesired
      secondary effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Outcome measures will be randomized and anonymized</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue score</measure>
    <time_frame>8 weeks</time_frame>
    <description>MFI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain index</measure>
    <time_frame>8 weeks</time_frame>
    <description>FIQ and Visual analogue scale (VAS) of pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differential gene expression</measure>
    <time_frame>8 weeks</time_frame>
    <description>RNAseq</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>8 weeks</time_frame>
    <description>SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANS (autonomic nervous system) dysfunction</measure>
    <time_frame>8 weeks</time_frame>
    <description>Plantar pressure maps</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subjective response to treatment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Custom-made questionnaire</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Fatigue Syndrome (CFS)</condition>
  <condition>Fibromyalgia (FM)</condition>
  <arm_group>
    <arm_group_label>Manual Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Manual Therapy</intervention_name>
    <description>8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N</description>
    <arm_group_label>Manual Therapy</arm_group_label>
    <other_name>Physiotherapy treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CFS and comorbid FM

          -  Not receiving hormone therapy

          -  Not suffering from other diseases

          -  Without previous history of cancer

          -  Not actively participating in any pharmacological trial

          -  Not taking medication for at least 12 hours before blood draw

          -  Having signed informed consent

        Exclusion Criteria:

        - Any uncompliance with what is described as inclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Garcia-Escudero, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Católica de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisa Oltra, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad Católica de Valencia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Garcia-Escudero, PhD</last_name>
    <phone>+34963637412</phone>
    <phone_ext>+34963637412</phone_ext>
    <email>maria.escudero@ucv.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisa Oltra, PhD</last_name>
    <phone>+34963637412</phone>
    <phone_ext>+34963637412</phone_ext>
    <email>elisa.oltra@ucv.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinicas Universitarias UCV</name>
      <address>
        <city>Valencia</city>
        <zip>46001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura López-Almansa, PhD</last_name>
      <phone>+34963920624</phone>
      <email>laura.lopezalmansa@ucv.es</email>
    </contact>
    <contact_backup>
      <last_name>Pablo Vera</last_name>
      <phone>+34963920624</phone>
      <email>fp.vera@ucv.es</email>
    </contact_backup>
    <investigator>
      <last_name>Francisco J Falaguera, BsC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.ucv.es/investigacion/grupos-de-investigacion/grupoclave/1431</url>
    <description>UCV Physiotherapy Research Group</description>
  </link>
  <reference>
    <citation>Espejo JA, García-Escudero M, Oltra E. Unraveling the Molecular Determinants of Manual Therapy: An Approach to Integrative Therapeutics for the Treatment of Fibromyalgia and Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. Int J Mol Sci. 2018 Sep 9;19(9). pii: E2673. doi: 10.3390/ijms19092673. Review.</citation>
    <PMID>30205597</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Universidad Católica de Valencia San Vicente Mártir</investigator_affiliation>
    <investigator_full_name>María García Escudero</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Manual Therapy</keyword>
  <keyword>Physiotherapy</keyword>
  <keyword>Chronic Fatigue Syndrome (CFS)</keyword>
  <keyword>Fibromyalgia (FM)</keyword>
  <keyword>RNAseq</keyword>
  <keyword>microRNA</keyword>
  <keyword>mechanomiR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

